Annals of Oncology Advance Access originally published online on February 7, 2005
Annals of Oncology 2005 16(4):618-624; doi:10.1093/annonc/mdi107
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Original articles |
Hematopoietic stem cell transplantation in mantle cell lymphoma
1 Department of Internal Medicine, Division of Oncology/Hematology, and 2 Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
* Correspondence to: Dr J. O. Armitage, Department of Internal Medicine, Division of Oncology-Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA. Tel: +1-402-559-7290; Fax: +1-402-559-8597; Email: joarmita{at}unmc.edu
Background: Patients with mantle cell lymphoma (MCL) have in general, lower response rates and overall survival (OS) than those with other B-cell non-Hodgkin's lymphomas. The role of hematopoietic stem cell transplantation (HSCT) in MCL is unclear. Hence we decided to study the clinical course of patients who received autologous and allogeneic HSCT for MCL.
Methods: Ninety-seven patients, (80 patients-autologous; 17 patients-allogeneic) who received a HSCT for mantle cell lymphoma were included in the study.
Results: The complete response rates at day 100 between the two groups were similar (73% vs. 62%). Day-100 mortality was higher in the allogeneic HSCT group (19% vs. 0%) (P < 0.01). The estimated 5-year relapse rates, 5-year event-free survival (EFS) and 5-year OS among the allogeneic HSCT patients were 21%, 44% and 49%, respectively, similar to 56%, 39% and 47% in the autologous group. Ten patients received HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + high-dose methotrexate and cytarabine) ± rituximab prior to transplant. There have been no relapses or deaths amongst these patients at a median follow-up of 16 months.
Conclusions: Patients treated with allogeneic HSCT had a lower relapse rate, but similar EFS and OS to autologous HSCT. Treatment of MCL with HyperCVAD ± rituximab followed by HSCT seems promising.
Key words: mantle cell lymphoma, autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, HyperCVAD
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al. Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma J. Clin. Oncol., March 10, 2009; 27(8): 1209 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies Ann. Onc., July 1, 2008; 19(7): 1327 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome Haematologica, January 1, 2007; 92(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|